Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Applied Therapeutics | AT-001 | diabetic complications | Phase I trials initiated |
Aravive Biologics | AVB-S6-500 | n/a | Phase I trials initiated enrolling 40 subjects in the U.S. |
Mallinckrodt | ExpressGraftC9T1 skin tissue | diabetic foot ulcers | Phase I trials initiated enrolling six subjects |
Pulmatrix | Pulmazole (PUR1900) | allergic bronchopulmonary aspergillosis related to asthma | Phase I trials initiated enrolling 42 subjects |
Vyera Pharmaceuticals | TUR-006 | toxoplasmosis | Phase I trials initiated |
MyoKardia | MYK-491 | dilated cardiomyopathy | Phase Ib trials initiated enrolling 64 subjects |
Arrowhead Pharmaceuticals | ARO-HBV | chronic hepatitis B virus infection | Phase I/II trials planned enrolling 30 subjects in New Zealand |
Audentes Therapeutics | AT342 | Crigler-Najjar syndrome | Phase I/II trials initiated |
Sienna Biopharmaceuticals | SNA-125 | psoriasis and the associated pruritus | Phase I trials initiated enrolling 15 subjects |
Imara | IMR-687 | sickle cell disease | Phase IIa trials initiated enrolling 50 subjects in the U.S. |
Nohla Therapeutics | NLA101 | acute myeloid leukemia | Phase II trials initiated enrolling 220 subjects in the U.S. |
Citius Pharmaceuticals, Inc. | Mino-Lok Therapy | catheter related bacteremias | Phase III trials initiated enrolling 700 subjects in the U.S. |
Intercept Pharmaceuticals | obeticholic acid | cirrhosis due to NASH | Phase III trials planned enrolling 540 subjects |
Pfizer | PF-04965842 | moderate to severe atopic dermatitis | Breakthrough Therapy designation granted by the FDA |
Abeona Therapeutics | ABO-202 | infantile Batten disease | Orphan Drug designation granted by the FDA |
AstraZeneca, Merck | selumetinib | neurofibromatosis type 1 | Orphan Drug designation granted by the FDA |
Xeris Pharmaceuticals | ready-to-use glucagon | Hyperinsulinemic Hypoglycemia | Orphan Drug designation granted by the FDA |
60 Degrees Pharmaceuticals | Tafenoquine | prevention of malaria | Priority Review designation granted by the FDA |
Genentech | Rituxan (rituximab) | pemphigus vulgaris | Priority Review designation granted by the FDA |
Janssen | Erleada (apalutamide) | non-metastatic castration-resistant prostate cancer | FDA approved |
NorthStar Medical Radioisotopes | RadioGenix System | Non-uranium Sourced Molybdenum-99 Production of Imaging Isotope Technetium-99m | FDA approved |
Upcoming Events
-
23Apr
-
07May
-
14May